CBD is considered a medicine in Finland and any CBD-infused product, whether for human or animal use, would be classified as a medicinal product. This report provides a comprehensive overview of the regulatory landscape of CBD in Finland ...
Sign up to our platform and you will have access to our latest business and regulatory news analysis, which keeps you updated with the latest hot topics in the sector.
Do the Novel Food regulations in Europe affect your business?
CBD as a Novel Food: the future for edibles in Europe
This new CBD-Intel report examines key aspects and drivers of the edibles market itself before looking in detail at the Novel Food regulations, both at EU level and in non-EU markets: notably the UK, as well as Switzerland and Norway.
Questions it considers and answers include whether CBD really is novel, whether approvals are likely to be generic or applicant-specific, how the Novel Food Catalogue and RASFF operate, and the costs of Novel Food applications.
This report also includes a 1-hour consultation call with CBD-Intel’s analyst team.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.
